AI in Oncology Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component, By Cancer Type, By Treatment Type, By Region & Competition, 2020-2030F

Description

The Global AI in Oncology Market was valued at USD 701.08 Million in 2024 and is projected to grow at a CAGR of 9.43% through 2030. The market is gaining strong momentum due to the increasing global burden of cancer and the growing demand for more accurate and efficient diagnostic and treatment options. Artificial intelligence is playing a transformative role in oncology by enabling early detection, image analysis, pathology interpretation, and personalized treatment planning. Innovations such as machine learning algorithms, deep learning, and integration with imaging technologies like MRI and CT scans are enhancing diagnostic precision. Regulatory approvals, such as the FDA's clearance of AI-powered cancer detection devices, and platforms like Tempus+ that support precision oncology, are accelerating adoption. Additionally, collaborations between healthcare providers, academic institutions, and AI companies are contributing to technological advancements. AI's ability to analyze vast datasets and support real-time clinical decisions is positioning it as a vital tool in cancer care, from diagnosis to post-treatment monitoring.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 701.08 Million
Market Size 2030	USD 1,201.02 Million
CAGR 2025-2030	9.43%
Fastest Growing Segment	Chemotherapy
Largest Market	North America

Key Market Drivers

Improving Diagnostic Accuracy

AI's ability to interpret medical images with high precision is driving its adoption in oncology. By identifying complex patterns in radiological scans such as MRIs and CTs, AI supports early cancer detection and improves diagnostic outcomes. A 2022 NCBI study emphasized how AI significantly enhances the detection of mammographic abnormalities, helping healthcare professionals diagnose cancer at earlier, more treatable stages. Unlike human interpretation, which can vary due to fatigue or experience, AI delivers consistent, objective analysis. This reduces the risk of misdiagnosis and increases confidence among clinicians. Moreover, AI-driven systems support cancer screening programs by efficiently analyzing high volumes of imaging and pathology data, improving throughput and reducing diagnostic delays across healthcare systems.

Key Market Challenges

Interoperability and Data Integration

Data fragmentation across healthcare systems is a major barrier to the seamless deployment of AI in oncology. Variations in electronic health record (EHR) platforms, imaging technologies, and data formats hinder the ability to integrate and standardize patient data. For AI systems to function effectively, comprehensive access to medical history, imaging records, and genomic profiles is critical. However, lack of compatibility and uniform standards often leads to inconsistent or incomplete data inputs. This affects the reliability of AI-driven recommendations and creates trust issues among healthcare providers. Data integration challenges also slow the training and validation of AI models, ultimately impacting clinical adoption and scalability.

Key Market Trends

AI-Driven Radiomics

AI-powered radiomics is emerging as a key trend, enabling the extraction of detailed imaging features that reflect tumor behavior and biological properties. By analyzing micro-patterns and textures in medical scans, AI systems can detect cancer early, even before clinical symptoms arise. Radiomics not only improves diagnosis but also plays a pivotal role in treatment personalization. AI can link image-based features with molecular and genetic data, guiding precision therapies. Additionally, radiomics tools assist in real-time treatment monitoring by tracking how tumors respond to specific interventions. These systems enhance decision-making and reduce variability in radiological assessments. As AI radiomics becomes more integrated into oncology workflows, it is redefining standards for cancer screening, diagnosis, and outcome prediction.

Key Market Players

Azra AI
IBM
Siemens Healthcare GmbH
Intel Corporation
GE HealthCare
NVIDIA Corporation
Digital Diagnostics Inc.
ConcertAI
Median Technologies
PathAI

Report Scope:

In this report, the Global AI in Oncology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

AI in Oncology Market, By Component:

Software Solutions
Hardware
Services

AI in Oncology Market, By Cancer Type:

Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Brain Tumor
Others

AI in Oncology Market, By Treatment Type:

Chemotherapy
Radiotherapy
Immunotherapy
Others

AI in Oncology Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Turkey
- Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global AI in Oncology Market.

Available Customizations:

Global AI in Oncology market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global AI in Oncology Market Outlook

5.1. Market Size & Forecast
- 5.1.1. By Value
5.2. Market Share & Forecast
- 5.2.1. By Component (Software Solutions, Hardware, Services)
- 5.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
- 5.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
- 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
- 5.2.5. By Company (2024)
5.3. Market Map

6. North America AI in Oncology Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By Component (Software Solutions, Hardware, Services)
- 6.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
- 6.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
- 6.2.4. By Country
6.3. North America: Country Analysis
- 6.3.1. United States AI In Oncology Market Outlook
  - 6.3.1.1. Market Size & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share & Forecast
    - 6.3.1.2.1. By Component
    - 6.3.1.2.2. By Cancer Type
    - 6.3.1.2.3. By Treatment Type
- 6.3.2. Canada AI In Oncology Market Outlook
  - 6.3.2.1. Market Size & Forecast
    - 6.3.2.1.1. By Value
  - 6.3.2.2. Market Share & Forecast
    - 6.3.2.2.1. By Component
    - 6.3.2.2.2. By Cancer Type
    - 6.3.2.2.3. By Treatment Type
- 6.3.3. Mexico AI In Oncology Market Outlook
  - 6.3.3.1. Market Size & Forecast
    - 6.3.3.1.1. By Value
  - 6.3.3.2. Market Share & Forecast
    - 6.3.3.2.1. By Component
    - 6.3.3.2.2. By Cancer Type
    - 6.3.3.2.3. By Treatment Type

7. Europe AI In Oncology Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Component (Software Solutions, Hardware, Services)
- 7.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
- 7.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
- 7.2.4. By Country
7.3. Europe: Country Analysis
- 7.3.1. France AI In Oncology Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By Component
    - 7.3.1.2.2. By Cancer Type
    - 7.3.1.2.3. By Treatment Type
- 7.3.2. Germany AI In Oncology Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By Component
    - 7.3.2.2.2. By Cancer Type
    - 7.3.2.2.3. By Treatment Type
- 7.3.3. United Kingdom AI In Oncology Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By Component
    - 7.3.3.2.2. By Cancer Type
    - 7.3.3.2.3. By Treatment Type
- 7.3.4. Italy AI In Oncology Market Outlook
  - 7.3.4.1. Market Size & Forecast
    - 7.3.4.1.1. By Value
  - 7.3.4.2. Market Share & Forecast
    - 7.3.4.2.1. By Component
    - 7.3.4.2.2. By Cancer Type
    - 7.3.4.2.3. By Treatment Type
- 7.3.5. Spain AI In Oncology Market Outlook
  - 7.3.5.1. Market Size & Forecast
    - 7.3.5.1.1. By Value
  - 7.3.5.2. Market Share & Forecast
    - 7.3.5.2.1. By Component
    - 7.3.5.2.2. By Cancer Type
    - 7.3.5.2.3. By Treatment Type

8. Asia-Pacific AI In Oncology Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Component (Software Solutions, Hardware, Services)
- 8.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
- 8.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
- 8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
- 8.3.1. China AI In Oncology Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Component
    - 8.3.1.2.2. By Cancer Type
    - 8.3.1.2.3. By Treatment Type
- 8.3.2. India AI In Oncology Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Component
    - 8.3.2.2.2. By Cancer Type
    - 8.3.2.2.3. By Treatment Type
- 8.3.3. Japan AI In Oncology Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Component
    - 8.3.3.2.2. By Cancer Type
    - 8.3.3.2.3. By Treatment Type
- 8.3.4. South Korea AI In Oncology Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By Component
    - 8.3.4.2.2. By Cancer Type
    - 8.3.4.2.3. By Treatment Type
- 8.3.5. Australia AI In Oncology Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By Component
    - 8.3.5.2.2. By Cancer Type
    - 8.3.5.2.3. By Treatment Type

9. South America AI In Oncology Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Component (Software Solutions, Hardware, Services)
- 9.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
- 9.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
- 9.2.4. By Country
9.3. South America: Country Analysis
- 9.3.1. Brazil AI In Oncology Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Component
    - 9.3.1.2.2. By Cancer Type
    - 9.3.1.2.3. By Treatment Type
- 9.3.2. Argentina AI In Oncology Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Component
    - 9.3.2.2.2. By Cancer Type
    - 9.3.2.2.3. By Treatment Type
- 9.3.3. Colombia AI In Oncology Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Component
    - 9.3.3.2.2. By Cancer Type
    - 9.3.3.2.3. By Treatment Type

10. Middle East and Africa AI In Oncology Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Component (Software Solutions, Hardware, Services)
- 10.2.2. By Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others)
- 10.2.3. By Treatment Type (Chemotherapy, Radiotherapy, Immunotherapy, Others)
- 10.2.4. By Country
10.3. MEA: Country Analysis
- 10.3.1. South Africa AI In Oncology Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Component
    - 10.3.1.2.2. By Cancer Type
    - 10.3.1.2.3. By Treatment Type
- 10.3.2. Saudi Arabia AI In Oncology Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Component
    - 10.3.2.2.2. By Cancer Type
    - 10.3.2.2.3. By Treatment Type
- 10.3.3. UAE AI In Oncology Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Component
    - 10.3.3.2.2. By Cancer Type
    - 10.3.3.2.3. By Treatment Type

11. Market Dynamics

11.1. Drivers
11.2. Challenges

12. Market Trends & Developments

12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches

13. Global AI In Oncology Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Azra AI.
- 15.1.1. Business Overview
- 15.1.2. Product Offerings
- 15.1.3. Recent Developments
- 15.1.4. Financials (As Reported)
- 15.1.5. Key Personnel
- 15.1.6. SWOT Analysis
15.2. IBM Corp.
15.3. Siemens Healthcare GmbH.
15.4. Intel Corporation.
15.5. GE HealthCare.
15.6. NVIDIA Corporation.
15.7. Digital Diagnostics Inc.
15.8. ConcertAI.
15.9. Median Technologies.
15.10. PathAI.